Adverse Drug Reaction Reporting Systems
"Adverse Drug Reaction Reporting Systems" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions.
| Descriptor ID |
D016907
|
| MeSH Number(s) |
E05.337.800.120 N02.421.668.320.120
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adverse Drug Reaction Reporting Systems".
Below are MeSH descriptors whose meaning is more specific than "Adverse Drug Reaction Reporting Systems".
This graph shows the total number of publications written about "Adverse Drug Reaction Reporting Systems" by people in this website by year, and whether "Adverse Drug Reaction Reporting Systems" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 1 | 2 |
| 2000 | 2 | 1 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 3 | 5 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 4 | 5 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 0 | 4 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 4 | 0 | 4 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 9 | 1 | 10 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
| 2022 | 0 | 2 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adverse Drug Reaction Reporting Systems" by people in Profiles.
-
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. Vaccine. 2024 03 07; 42(7):1812-1825.
-
Reliability and validity of PRO-CTCAE? daily reporting with a 24-hour recall period. Qual Life Res. 2023 Jul; 32(7):2047-2058.
-
Heterogeneity of Drug Allergies and Reaction Lists in Two U.S. Health Care Systems' Electronic Health Records. Appl Clin Inform. 2022 05; 13(3):741-751.
-
Intelligent Telehealth in Pharmacovigilance: A Future Perspective. Drug Saf. 2022 05; 45(5):449-458.
-
Cardiovascular safety profile of taxanes and vinca alkaloids: 30 years FDA registry experience. Open Heart. 2021 12; 8(2).
-
Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink. JAMA. 2021 10 12; 326(14):1375-1377.
-
Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States. JAMA Netw Open. 2021 09 01; 4(9):e2124502.
-
Hypothalamic-Pituitary-Adrenal Activity in Adverse Events Reporting After Placebo Administration. Clin Pharmacol Ther. 2021 11; 110(5):1349-1357.
-
Augmenting aer2vec: Enriching distributed representations of adverse event report data with orthographic and lexical information. J Biomed Inform. 2021 07; 119:103833.
-
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials. 2021 02; 18(1):104-114.